About
Larimar Therapeutics
LRMR.US
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Profile
- Company Name
- Larimar Therapeutics, Inc.
- Market
- NasdaqGM
- Founded
- --
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.larimartx.com